CV 301

Drug Profile

CV 301

Alternative Names: CEA-MUC-1-TRICOM Vaccine; CEA-MUC-1/TRICOM; CV-301; CVAC-301; falimarev; inalimarev; PANVAC; PANVAC V/F; PANVAC-VF

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therion Biologics
  • Developer BN ImmunoTherapeutics; Duke University; National Cancer Institute (USA)
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Non-small cell lung cancer
  • Discontinued Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 08 Nov 2017 Bavarian Nordic plans a phase II trial for Non-small cell lung cancer (Combination therapy; First-line therapy) by the end of 2017
  • 20 Oct 2017 National Cancer Institute plans a phase II trial of the combination of rilimogene galvacirepvec-rilimogene glafolivec, CV 301 and MSB 0011359C for Prostate cancer (Combination therapy) in USA (NCT03315871)
  • 15 May 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (SC) (Bavarian Nordic company pipeline, July 2017) (NCT02840994)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top